专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06436722B1 Device and method for integrated diagnostics with multiple independent flow paths 失效
标题翻译：具有多个独立流路的集成诊断的装置和方法
公开(公告)号：US06436722B1
公开(公告)日：2002-08-20
申请号：US09551496
申请日：2000-04-18
申请人： Scott M. Clark , Robert H. Suva , Michael R. Kepron , Stanislaw Barski, Jr. , Erwin F. Workman, Jr.
发明人： Scott M. Clark , Robert H. Suva , Michael R. Kepron , Stanislaw Barski, Jr. , Erwin F. Workman, Jr.
IPC分类号： G01N33543
CPC分类号： G01N33/558 , G01N33/54366 , Y10T436/11 , Y10T436/12 , Y10T436/255
摘要： Invention performs an assay to determine presence or quantity of specific analyte in fluid sample. Representative device has two separate flow paths established sequentially in device with a single user activation step. First flow path delivers sample, and conjugate soluble binding reagents to solid phase. If analyte is present, an analyte:conjugate complex is formed and immobilized. Sample volume delivered by first path determined by absorbent capacity of solid phase, and not by amount of sample added to device. User need not measure sample volume. Sample/conjugate mixture is prevented from entering second flow path because capillary and surface energy of second flow path prevent it from being wetted by this mixture. Second flow path allows wash reagent to remove unbound conjugate and sample from solid phase to the absorbant, and optionally deliver detection reagents. Adaptable for many formats including, sandwich immunoassays, colloidal gold, sol particle, heterogeneous generic capture, and competitive assays.
摘要翻译：本发明进行测定以确定流体样品中特定分析物的存在或数量。代表性设备具有在具有单个用户激活步骤的设备中顺序建立的两个单独的流路径。第一流路将样品和可溶性结合试剂结合到固相中。如果存在分析物，则形成并固定分析物：缀合物。由第一路径输送的样品体积由固相的吸收能力确定，而不是通过添加到设备的样品量。用户不需要测量样品量。防止样品/共轭物混合物进入第二流路，因为第二流路的毛细管和表面能阻止其被该混合物润湿。第二流路允许洗涤剂将未结合的结合物和样品从固相除去到吸收剂，并且任选地递送检测试剂。适用于多种形式，包括夹心免疫测定，胶体金，溶胶颗粒，异种通用捕获和竞争性测定。

2. 发明授权

US06887487B2 Injectable compositions for the controlled delivery of pharmacologically active compound 有权
公开(公告)号：US06887487B2
公开(公告)日：2005-05-03
申请号：US10274445
申请日：2002-10-18
申请人： Yerramilli V. S. N. Murthy , Robert H. Suva
发明人： Yerramilli V. S. N. Murthy , Robert H. Suva
IPC分类号： A61K9/00 , A61K9/10 , A61K31/137 , A61K31/138 , A61K31/165 , A61K31/18 , A61K31/245 , A61K31/4704 , A61K31/496 , A61K31/505 , A61K31/65 , A61K31/7036 , A61K31/7048 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/22 , A61K47/26 , A61K47/32 , A61K47/34 , A61P23/02 , A61P31/04
CPC分类号： A61K31/00 , A61K9/0019 , A61K9/0024 , A61K31/24 , A61K31/496 , A61K31/65 , A61K31/7034 , A61K31/7048 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/22 , A61K47/26 , A61K2300/00
摘要： The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a periods of up to 15 days or even longer. Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.

3. 发明申请

US20080306152A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE 审中-公开
标题翻译：含有氟虫腈的组合物及其使用方法
公开(公告)号：US20080306152A1
公开(公告)日：2008-12-11
申请号：US12143097
申请日：2008-07-28
申请人： Yerramilli V.S.N. Murthy , Robert H. Suva
发明人： Yerramilli V.S.N. Murthy , Robert H. Suva
IPC分类号： A61K31/22 , A61P31/04
CPC分类号： A61K31/222 , A61K9/0019 , A61K9/0024 , A61K31/205 , A61K31/23 , A61K49/0004 , C07C317/32 , A61K2300/00
摘要： The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of the following: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate. In another embodiment the prodrug is converted into the florfenicol in vivo by the action of one or more endogenous esterases. The invention also provides new compounds, pharmaceutical compositions containing the compounds, and methods for their administration.
摘要翻译：本发明提供了用于向哺乳动物施用氟苯尼考的组合物和方法。组合物在药学上可接受的载体中含有氟苯尼考的前药。在一个实施方案中，前药是氟苯尼考的酯化形式。合适的前药的实例包括以下的一种或组合的一种或其组合：氟苯尼考乙酸酯，氟苯尼考丙酸酯，氟苯尼考丁酸酯，氟苯尼考戊酸酯，氟苯尼考己酸酯，氟苯尼考辛酸酯，氟苯尼考辛酸酯，氟苯尼考羧酸酯，氟苯尼考十一酸酯，氟苯尼考十二酸酯和氟苯尼考邻苯二甲酸酯。在另一个实施方案中，前体药物通过一种或多种内源性酯酶的作用在体内转化成氟苯尼考。本发明还提供新的化合物，含有这些化合物的药物组合物及其给药方法。

4. 发明授权

US07786167B2 Compositions containing prodrugs of florfenicol and methods of use 失效
公开(公告)号：US07786167B2
公开(公告)日：2010-08-31
申请号：US11907182
申请日：2007-10-10
申请人： Yerramilli V. S. N. Murthy , Robert H. Suva
发明人： Yerramilli V. S. N. Murthy , Robert H. Suva
IPC分类号： A61K31/205 , A61K31/53 , A61K31/50 , A61K31/505 , A61K31/44
CPC分类号： A61K31/222 , A61K9/0019 , A61K9/0024 , A61K31/205 , A61K31/23 , A61K49/0004 , C07C317/32 , A61K2300/00
摘要： The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of the following: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate. In another embodiment the prodrug is converted into the florfenicol in vivo by the action of one or more endogenous esterases. The invention also provides new compounds, pharmaceutical compositions containing the compounds, and methods for their administration.

5. 发明授权

US07033599B2 Injectable compositions for the controlled delivery of pharmacologically active compound 失效
标题翻译：用于控制递送药理学活性化合物的可注射组合物
公开(公告)号：US07033599B2
公开(公告)日：2006-04-25
申请号：US10403100
申请日：2003-03-28
申请人： Yerramilli V.S.N. Murthy , Robert H. Suva
发明人： Yerramilli V.S.N. Murthy , Robert H. Suva
IPC分类号： A61K9/00
CPC分类号： A61K31/00 , A61K9/0019 , A61K9/0024 , A61K31/24 , A61K31/496 , A61K31/65 , A61K31/7034 , A61K31/7048 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/22 , A61K47/26 , A61K2300/00
摘要： The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8–C22 fatty acid, and preferably may be a saturated or unsaturated C10–C18 fatty acid. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a periods of up to 15 days or even longer. Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.
摘要翻译：本发明提供用于延长释放时间并降低药理活性化合物的毒性的组合物和方法。化合物包含药理活性化合物的盐与亲脂性抗衡离子和药学上可接受的水溶性溶剂组合在一起形成可注射组合物。亲油抗衡离子可以是饱和或不饱和的C 12 -C 22脂肪酸，优选可以是饱和或不饱和的C 10 -C 18 脂肪酸。当注射到哺乳动物中时，组合物的至少一部分随时间沉淀并释放活性化合物。因此，组合物在哺乳动物中形成缓慢释放活性化合物的药物贮库。因此，本发明使得能够提供活性化合物的受控剂量给药长达15天甚至更长时间。根据本发明可以施用许多化合物，包括但不限于替米考星，土霉素，美托洛尔，氟西汀，罗红霉素和头孢噻吩。

6. 发明授权

US07439268B2 Compositions containing prodrugs of florfenicol and methods of use 失效
标题翻译：含有氟苯尼考前药的组合物和使用方法
公开(公告)号：US07439268B2
公开(公告)日：2008-10-21
申请号：US10623114
申请日：2003-07-18
申请人： Yerramilli V. S. N. Murthy , Robert H. Suva
发明人： Yerramilli V. S. N. Murthy , Robert H. Suva
IPC分类号： A61K31/205 , A61K31/53 , A61K31/50 , A61K31/505 , A61K31/44
CPC分类号： A61K31/222 , A61K9/0019 , A61K9/0024 , A61K31/205 , A61K31/23 , A61K49/0004 , C07C317/32 , A61K2300/00
摘要： The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of the following: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate. In another embodiment the prodrug is converted into the florfenicol in vivo by the action of one or more endogenous esterases. The invention also provides new compounds, pharmaceutical compositions containing the compounds, and methods for their administration.
摘要翻译：本发明提供了用于向哺乳动物施用氟苯尼考的组合物和方法。组合物在药学上可接受的载体中含有氟苯尼考的前药。在一个实施方案中，前药是氟苯尼考的酯化形式。合适的前药的实例包括以下的一种或组合的一种或其组合：氟苯尼考醋酸酯，氟苯尼考丙酸酯，氟苯尼考丁酸酯，氟苯尼考戊酸酯，氟苯尼考己酸酯，氟苯尼考辛酸酯，氟苯尼考辛酸酯，氟苯尼考乳酸酯，氟苯尼考十一酸酯，氟苯尼考十二酸酯和氟苯尼考邻苯二甲酸酯。在另一个实施方案中，前体药物通过一种或多种内源性酯酶的作用在体内转化成氟苯尼考。本发明还提供新的化合物，含有这些化合物的药物组合物及其给药方法。

7. 发明授权

US07404964B2 Injectable compositions for the controlled delivery of pharmacologically active compound 有权
标题翻译：用于控制递送药理学活性化合物的可注射组合物
公开(公告)号：US07404964B2
公开(公告)日：2008-07-29
申请号：US11088922
申请日：2005-03-25
申请人： Yerramilli V.S.N. Murthy , Robert H. Suva
发明人： Yerramilli V.S.N. Murthy , Robert H. Suva
IPC分类号： A61K9/00
CPC分类号： A61K31/00 , A61K9/0019 , A61K9/0024 , A61K31/24 , A61K31/496 , A61K31/65 , A61K31/7034 , A61K31/7048 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/22 , A61K47/26 , A61K2300/00
摘要： The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a periods of up to 15 days or even longer. Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.
摘要翻译：本发明提供用于延长释放时间并降低药理活性化合物的毒性的组合物和方法。化合物包含药理活性化合物的盐与亲脂性抗衡离子和药学上可接受的水溶性溶剂组合在一起形成可注射组合物。亲油抗衡离子可以是饱和或不饱和的C 12 -C 22脂肪酸，优选可以是饱和或不饱和的C 10 -C 18 脂肪酸。当注射到哺乳动物中时，组合物的至少一部分随时间沉淀并释放活性化合物。因此，组合物在哺乳动物中形成缓慢释放活性化合物的药物贮库。因此，本发明使得能够提供活性化合物的受控剂量给药长达15天甚至更长时间。根据本发明可以施用许多化合物，包括但不限于替米考星，土霉素，美托洛尔，氟西汀，罗红霉素和头孢噻吩。

8. 发明授权

US07662861B2 Compositions containing prodrugs of florfenicol and methods of use 失效
标题翻译：含有氟苯尼考前药的组合物和使用方法
公开(公告)号：US07662861B2
公开(公告)日：2010-02-16
申请号：US11700069
申请日：2007-01-31
申请人： Yerramilli V. S. N. Murthy , Robert H. Suva
发明人： Yerramilli V. S. N. Murthy , Robert H. Suva
IPC分类号： A01N37/12 , A01N37/44 , A61K31/24 , A01N37/02 , A01K31/22 , C07C69/66
CPC分类号： A61K31/222 , A61K9/0019 , A61K9/0024 , A61K31/205 , A61K31/23 , A61K49/0004 , C07C317/32 , A61K2300/00
摘要： The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of the following: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate. In another embodiment the prodrug is converted into the florfenicol in vivo by the action of one or more endogenous esterases. The invention also provides new compounds, pharmaceutical compositions containing the compounds, and methods for their administration.
摘要翻译：本发明提供了用于向哺乳动物施用氟苯尼考的组合物和方法。组合物在药学上可接受的载体中含有氟苯尼考的前药。在一个实施方案中，前药是氟苯尼考的酯化形式。合适的前药的实例包括以下的一种或组合的一种或其组合：氟苯尼考乙酸酯，氟苯尼考丙酸酯，氟苯尼考丁酸酯，氟苯尼考戊酸酯，氟苯尼考己酸酯，氟苯尼考辛酸酯，氟苯尼考辛酸酯，氟苯尼考羧酸酯，氟苯尼考十一酸酯，氟苯尼考十二酸酯和氟苯尼考邻苯二甲酸酯。在另一个实施方案中，前体药物通过一种或多种内源性酯酶的作用在体内转化成氟苯尼考。本发明还提供新的化合物，含有这些化合物的药物组合物及其给药方法。

9. 发明授权

US07053249B2 Metal chelates and methods of using them for time-resolved fluorescence 失效
标题翻译：金属螯合物及其使用时间分辨荧光的方法
公开(公告)号：US07053249B2
公开(公告)日：2006-05-30
申请号：US10280330
申请日：2002-10-25
申请人： Yerramilli Murthy , Robert H. Suva
发明人： Yerramilli Murthy , Robert H. Suva
IPC分类号： C07C49/115 , G01N33/543 , G01N33/53
CPC分类号： C07C49/84 , C07C45/455 , C07C49/788 , C07C49/813 , C07C49/92 , C07C51/44 , C07C225/22 , C07C255/56 , C07D213/50 , C07F9/5345 , C07C57/04
摘要： β-diketone fluorescent tags are disclosed, particularly those enabling the use of excitation energy in the near visible or visible spectrum. In some cases, these tags allow the use of cost-effective excitation devices such as LED's. The compounds form fluorescent chelates (complexes) with lanthanide (III) rare earth metal ions (such as Eu3+). The fluorescent complex may be included in a latex microparticle, such as a styrene latex particle. Ideally, the complex has an absorption maximum λ equal to or greater than 360 nm, and the compound is characterized by a pKa
摘要翻译：公开了β-二酮荧光标签，特别是能够在近似可见或可见光谱中使用激发能的那些。在某些情况下，这些标签允许使用具有成本效益的激励装置，如LED。这些化合物与镧系元素（III）稀土金属离子（如Eu3 +）形成荧光螯合物（络合物）。荧光复合物可以包括在胶乳微粒如苯乙烯胶乳颗粒中。理想地，复合物具有等于或大于360nm的吸收最大λ，并且该化合物的特征在于pKa <9.0。还公开了用于检测靶分子（例如免疫测定）的试剂盒和方法。这些方法和试剂盒通常使用配体结合靶分子和与配体连接的标记试剂。上述荧光复合物是标记试剂的至少一部分。用于从样品检测荧光的装置包括产生等于或大于360nm的照射能量λ的照射能量源; 用于检测来自样品的荧光的检测器; 以及用于将样品保持在被能量源照射的位置的样品保持器。优选使用发光二极管作为照射能量源。

10. 发明授权

US06946137B2 Methods for the controlled delivery of pharmacologically active compounds 有权
标题翻译：用于控制递送药理活性化合物的方法
公开(公告)号：US06946137B2
公开(公告)日：2005-09-20
申请号：US10418946
申请日：2003-04-18
申请人： Yerramilli V. S. N. Murthy , Robert H. Suva
发明人： Yerramilli V. S. N. Murthy , Robert H. Suva
IPC分类号： A61K20060101 , A61K9/00 , A61K31/65 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/22 , A61K47/26
CPC分类号： A61K31/65 , A61K9/0019 , A61K9/0024 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/22 , A61K47/26
摘要： The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. The compounds precipitate in aqueous environments. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a period of up to 15 days or even longer. Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.
摘要翻译：本发明提供用于延长释放时间并降低药理活性化合物的毒性的组合物和方法。化合物包含药理活性化合物的盐与亲脂性抗衡离子和药学上可接受的水溶性溶剂组合在一起形成可注射组合物。亲油抗衡离子可以是饱和或不饱和的C 12 -C 22脂肪酸，优选可以是饱和或不饱和的C 10 -C 18 脂肪酸。化合物在水性环境中沉淀。当注射到哺乳动物中时，组合物的至少一部分随时间沉淀并释放活性化合物。因此，组合物在哺乳动物中形成缓慢释放活性化合物的药物贮库。因此，本发明使得能够提供活性化合物的受控剂量给药长达15天甚至更长时间。根据本发明可以施用许多化合物，包括但不限于替米考星，土霉素，美托洛尔，氟西汀，罗红霉素和头孢噻吩。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式